Grab Source And Key Details Here: Company Presentation.
And as mentioned above, NBY has several potential catalysts that could help provide a breakout spark. Check these out:
No. 1 NBY Potential Catalyst - Explosive Volatility Potential From Tiny Float
According to the Yahoo Finance website, NBY has a tiny low float.
The website reports this profile to have approximately 2.55Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news in 2023 provide a near term spark?
No. 2 NBY Potential Catalyst - Analyst Targets Could Suggest As Much As 1,400% Potential Upside
Edward Woo, an analyst at Ascendiant Capital Markets, has tagged NBY with a $12.00 price target.
From this past Friday's close, that provides NBY with an incredible upside potential of 1,400%.
Here's some key highlights from his report:
- Avenova unit growth again: Avenova sales were $2.1Mn. Avenova had continued year-over-year growth in online Avenova Spray unit sales.
- DERMAdoctor contribution: DERMAdoctor sales were $1.0Mn, and reflects the 4 rd full quarter of sales since the acquisition closed in November 2021 (in Q4 2021). In September 2021, NovaBay announced the acquisition of privately held DERMAdoctor for ~$12Mn (in cash).
- DERMAdoctor: DERMAdoctor produces and sells more than 30 products under lines that include Ain’t Misbehavin’, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge. Its products are designed to address acne, aging skin, dark spots, dry skin, eczema, and many other skin conditions. DERMAdoctor sells its products through major retailers such as Macy’s, QVC, Costco, digital beauty retailers such as SkinStore and Amazon, as well as its own website. DERMAdoctor also has a large and growing network of international distributors and retailers. DERMAdoctor’s management has joined the NovaBay management team.
- Management long term positive: NovaBay is making good progress to market its Avenova product to the 41 million Americans ($600Mn market opp.) who suffer from blepharitis and related eye symptoms. In addition, the acquisition of DERMAdoctor allows strong growth and synergy opp's in the global market for cosmetic skincare products. NovaBay plans to launch a broad range of complementary eye and skin care products. The company also plans to leverage operational synergies and sales/distribution relationships.
- We remain positive: Despite st-ock and fi-nan-cial results volatility, we believe that NovaBay is a compelling ... story. The company’s focus in 2023 is to drive Avenova and DERMAdoctor sales to consumers by focusing on current products as well as new product launches.
No. 3 NBY Potential Catalyst - Company's Products Appear On Flagship Shopping Channel "QVC"
NovaBay Pharmaceuticals Announces DERMAdoctor’s KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to be Featured on QVC at a Special Price
Chief Product Officer Dr. Audrey Kunin to showcase KP Duty combo with supercharged exfoliators and moisturizers to help rapidly lift away dry, rough bumps and reveal healthier looking skin
EMERYVILLE, Calif., June 12, 2023--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Dr. Audrey Kunin will appear on QVC®’s Girls Night In with Courtney & Jane on Tuesday, June 13, 2023 at 10:00 p.m. Eastern time to showcase DERMAdoctor®’s system for dry, rough, bumpy skin. The two-piece Ultra Duo set of KP Duty Scrub and KP Duty Lotion, both in the 8-ounce size, will be available at QVC for a special price of $56.50.
"Our KP Duty Ultra Duo is specially formulated as a two-step system to help temporarily exfoliate, smooth, and hydrate dry, rough, and bumpy skin on the body, together with moisturizers to help hydrate for softer, more supple and smoother looking skin," said Dr. Audrey Kunin, a board-certified dermatologist. "Like all DERMAdoctor products, KP Duty Scrub and KP Duty Lotion are dermatologist tested to be non-irritating and ideal for year-round use."
KP Duty Body Scrub is formulated with a 10% complex of Alpha Hydroxy Acids and Polyhydroxy Acids for a dual action physical and chemical exfoliation of the skin that temporarily removes the dead surface skin cells, and a hydrating botanical blend of Evening Primrose, Black Currant Seed Oil, Borage Seed Oil, and White Tea Leaf Extract.
KP Duty Lotion is formulated with a 10% complex of Alpha Hydroxy Acids and Polyhydroxy Acids to temporarily exfoliate the skin to help alleviate skin roughness and improve the appearance of skin texture and smoothness, along with ceramides, botanicals and the humectant Urea to help temporarily hydrate and moisturize the skin.
Dr. Audrey Kunin is an author, clinician, educator, television personality and recognized trailblazer in the skincare industry. DERMAdoctor delivers on the promise that skin therapy can be simple and easy. All DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns.
Read the full article here.
No. 4 NBY Potential Catalyst - Chinese Order Demonstrates Growing Presence In International Markets
NovaBay Pharmaceuticals Fulfills $1Mn Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings
EMERYVILLE, Calif., May 01, 2023--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1Mn order for NovaBay’s NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this order and expects to recognize this revenue in the second quarter of 2023.
"NeutroPhase is the safest, purest and most powerful hypochlorous acid wound cleanser on the market yet is gentle, non-irritating and non-sensitizing to skin and new tissue," said Justin Hall, CEO of NovaBay Pharmaceuticals. "Importantly, NeutroPhase differentiates itself in the marketplace because it does not contain the toxic chemicals found in many other wound care products. We proudly manufacture NeutroPhase in the U.S. in large batch quantities through a proprietary process."
"The efficacy of NeutroPhase is unparalleled in the wound care market. We are proud of our long-term partnership with NovaBay and are delighted to make this high-quality product available to our healthcare customers in China," said Paul Li, Chairman of China Pioneer.
Read the full article here.
No. 5 NBY Potential Catalyst - The Wound Care Market Could Be A "Larger Part" Of NBY's 2023 Business
PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market
PhaseOne is uniquely formulated with NovaBay Pharmaceuticals’ unique and proprietary hypochlorous acid
NASHVILLE, Tenn. & EMERYVILLE, Calif., January 17, 2023--(BUSINESS WIRE)--PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid.
"We expect wound care to be a larger part of our business in 2023 and we are excited to partner with PhaseOne Health to grow our sales in the coming year," said Justin Hall, CEO of NovaBay Pharmaceuticals.
Kris Perkins, Managing Director of PhaseOne Health, further explained, "We are building on triple-digit percentage growth over the last few years by aligning with key opinion leaders and advisors to expand our commercial programs in 2023. Combining our past commercial success with recent results in new clinical applications positions us well to pursue synergistic business and protocol development with other companies and providers to address large market opportunities not only in wound care but in other surgical applications as well."
PhaseOne differentiates itself in the wound care market by utilizing NovaBay’s unique formulation of HOCI. Through its proprietary manufacturing process and amber glass bottle, NovaBay ensures the safest, purest, most powerful HOCl wound cleanser on the market. Its effectiveness is independently documented in the study Comparative Antimicrobial Activity of Commercial Wound Care Solutions on Bacterial and Fungal Biofilms (Harriott, PhD et al) published in the peer-reviewed journal Annals of Plastic Surgery.
Read the full article here.
NBY Recap - The Top Potential Catalysts For This NYSE American Past Champ
No. 1 - Explosive Volatility Potential From Tiny Float
No. 2 - Analyst Targets Could Suggest As Much As 1,400% Potential Upside
No. 3 - Company's Products Appear On Flagship Shopping Channel "QVC"
No. 4 - Chinese Order Demonstrates Growing Presence In International Markets
No. 5 - The Wound Care Market Could Be A "Larger Part" Of NBY's 2023 Business
Coverage is officially reinitiated on NBY. When time allows, do this: